Intensive Triglyceride Lowering with Olezarsen Does Not Reduce Coronary Plaque Progression in the Essence-TIMI 73b CCTA Sub Study
Key Points Triglyceride-rich lipoproteins (TRLs) and remnant cholesterol have been increasingly implicated in atherosclerotic cardiovascular disease risk,... Read more.
Community-Engaged Barbershop-Based Hypertension Prevention in Black Men: Insights from the CLIP Trial
Key Points Black men in the United States experience disproportionately high rates of hypertension (HTN) and related mortality, driven by structural... Read more.
Evolocumab Reduces CV Risk in Diabetic Patients Without ASCVD: VESALIUS-CV Trial
Key Points Lowering low-density lipoprotein cholesterol (LDL-C) is a cornerstone of cardiovascular prevention, with statins forming the foundation of therapy. While... Read more.
KARDINAL Trial: Tonlamarsen Reduces Angiotensinogen Levels but Does Not demonstrate additive SBP Benefit in Single Versus Five Doses
Key Points Hypertension (HTN) remains a leading modifiable cardiovascular risk factor, with many patients exhibiting persistent elevations... Read more.
Home-Delivered DASH Diet Groceries Improve BP and LDL-C in African American Patients with Hypertension: The GoFreshRx Trial
Key Points Hypertension (HTN) disproportionately affects African- American adults in the United States, with structural barriers such as limited access to healthy... Read more.
Family-Based Intervention Reduced Blood Pressure in Adults in Rural China: The Healthy Family Program
Key Points: A community- and family-based intervention can reduce systolic blood pressure (SBP) across both hypertensive and normotensive adults in rural Chinese... Read more.
DASH Diet Patterned Groceries Help Reduce Blood Pressure in Black Adults: The GOFRESH Trial
Key Points: The GOFRESH trial, a parallel-group randomized study, was conducted to determine the effects of low sodium-DASH groceries on systolic BP. Home-delivered... Read more.
PCSK9-inhibitors Do Not Reduce Early Cardiac Allograft Vasculopathy: The CAVIAR Trial
Key Points The CAVIAR trial enrolled recent heart transplant recipients to receive either receive alirocumab 150 mg subcutaneously every 2 weeks or placebo, in addition... Read more.
A Liberal Transfusion Strategy Does Not Significantly Reduce MACE vs a Restrictive Strategy in High Cardiac Risk Patients: The TOP Trial
Key Points: In patients at high cardiac risk undergoing major vascular or general surgery and developing postoperative anemia, a liberal transfusion strategy (Hb... Read more.
Providing Healthy Food + Nutrition Counseling Improved Quality of Life in HF Patients: FOOD-HF Trial
Key Points: The FOOD‑HF Trial was a single center randomized trial that enrolled 150 patients within two weeks of discharge for acute HF. Participants were randomized... Read more.